BlackRock Group’s Agios Pharmaceuticals AGIO Stock Holding History

BlackRock Group’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4.36M	Sell	104,407 -95,154	-48%	-$4.99M	﹤0.01%	1268
2016 Q3	$10.5M	Buy	199,561 +68,435	+52%	+$2.98M	0.01%	919
2016 Q2	$5.49M	Buy	131,126 +114,979	+712%	+$5.68M	﹤0.01%	1062
2016 Q1	$656K	Buy	16,147 +2,938	+22%	+$126K	﹤0.01%	2120
2015 Q4	$857K	Sell	13,209 -165	-1%	-$10.8K	﹤0.01%	1984
2015 Q3	$944K	Buy	13,374 +100	+0.8%	+$9.77K	﹤0.01%	1916
2015 Q2	$1.48M	Sell	13,274 -78,245	-85%	-$8.43M	﹤0.01%	1723
2015 Q1	$8.63M	Buy	91,519 +3,762	+4%	+$422K	﹤0.01%	994
2014 Q4	$9.83M	Buy	87,757 +21,719	+33%	+$1.94M	0.01%	967
2014 Q3	$4.05M	Buy	66,038 +21,638	+49%	+$933K	﹤0.01%	1160
2014 Q2	$2.03M	Buy	44,400 +21,600	+95%	+$880K	﹤0.01%	1455
2014 Q1	$893K	Hold	22,800	–	–	﹤0.01%	2039
2013 Q4	$546K	Sell	22,800 -829	-4%	-$18.9K	﹤0.01%	2201
2013 Q3	$661K	Buy	+23,629	New	+$652K	﹤0.01%	2115

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Group's AGIO Position: Q4 2016 in Review

BlackRock Group reduced its Agios Pharmaceuticals (AGIO) stake by 48% in Q4 2016, selling an estimated $4.99M and leaving 104,407 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #1268.

BlackRock Group first reported a position in AGIO in Q3 2013 and has held it in 14 quarters since. The position peaked at $10.5M in Q3 2016. 161 funds tracked by Wall St. Rank hold AGIO as of Q4 2016.

BlackRock Group held 104,407 shares of Agios Pharmaceuticals worth $4.36M as of Q4 2016.
BlackRock Group sold 95,154 Agios Pharmaceuticals shares in Q4 2016, an estimated $4.99M.
Agios Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1268 holding.
BlackRock Group first reported a position in Agios Pharmaceuticals in Q3 2013 and has held it in 14 quarters since.
BlackRock Group's Agios Pharmaceuticals position peaked at $10.5M in Q3 2016.
161 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.